Natco Pharma unveils additional strengths of generic Revlimid in U.S.
The Hindu
With the launch, the companies have made available all the strengths of lenalidomide in the U.S. market,
Natco Pharma has launched its generic version of Celgene Corporation’s cancer drug Revlimid (lenalidomide capsules) in additional strengths in the United States.
The 2.5 mg and 20 mg strengths of the prescription medicine used in adults for the treatment of multiple myeloma has been launched through its marketing partner Teva Pharmaceuticals, which is a U.S. affiliate of Teva Pharmaceutical Industries.
With the launch, the companies have made available all the strengths of lenalidomide in the U.S. market, Natco said in a release on March 10.

Scaling Artificial Intelligence(AI) at the speed at which consultants project is not possible by the laws of physics and may not be environmentally sustainable, said Tanvir Khan, who is the Executive Vice President and Chief Operating Officer of NTT DATA North America, part of the Japanese technology services and data centre company NTT Data, in an interview with The Hindu.












